EGFR and neoplasm: For instance, dual blockade of EGFR and MET may overcome MET-amplified or MET-driven resistance, whereas combining EGFR-TKIs with PD-1/PD-L1 inhibitors can potentially counteract TKI-induced upregulation of PD-L1 and the induction of an immunosuppressive tumor microenvironment (TME).